---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-229076"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-05-18T20:51:59+00:00"
generated_at: "2026-05-18T20:53:37.980012+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences WVE-006 phase 1b/2a data shows MZ-like phenotype with monthly dosing, FDA feedback expected mid-2026

## Summary
- WVE-006 achieved 64.4% wild-type M-AAT (matching protective MZ phenotype) and 70.5% reduction in toxic Z-AAT in 200 mg biweekly cohort.
- Monthly 400 mg dosing yielded similar results: 58.7% M-AAT, 67.7% Z-AAT reduction, and 13.6 µM total AAT.
- Dynamic AAT production restored during acute phase responses (common cold); CRP and AAT strongly correlated (r=0.73, p<0.001).
- WVE-006 well tolerated with no serious AEs or liver toxicities; monthly subcutaneous dosing confirmed feasible.
- Wave expects FDA feedback on accelerated approval pathway mid-2026; 600 mg monthly cohort data due H2 2026.

## SEC filing metadata
- accession: 0001193125-26-229076
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-05-18T20:51:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/0001193125-26-229076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526229076/d154261d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-229076
- JSON: https://secwatch.observer/filing/0001193125-26-229076.json
- Plain text: https://secwatch.observer/filing/0001193125-26-229076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.